RxDoctor Payments Data

Patricia Leone, NP

Psychiatric/Mental Health · Watertown, NYNPI 1457789984

Payments from drug & device makers

$2,182in general payments, 2019–2025

Across 86 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$756
  • Otsuka America Pharmaceutical, Inc.$352
  • AbbVie$352
  • Alkermes, Inc.$239
  • Johnson & Johnson$102
  • Supernus Pharmaceuticals, Inc.$95
  • plus $286 from 9 others

What the payments were for

  • Food & beverage$2,04994%
  • Education$1336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,182 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$11,034
Medicare patients
37
Services billed
137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate70$248,019
Invega TrinzaPaliperidone Palmitate15$144,722
Abilify MaintenaAripiprazole44$121,933
VraylarCariprazine Hcl25$39,402
RexultiBrexpiprazole27$38,950
CaplytaLumateperone Tosylate14$23,546
ZyprexaOlanzapine11$10,693
InvegaPaliperidone12$6,513
Lurasidone Hcl61$6,481
Paliperidone ErPaliperidone61$5,326
Clozapine59$2,629
Ziprasidone Hcl38$2,567
Duloxetine Hcl137$2,525
Buspirone Hcl186$2,269
Lisdexamfetamine Dimesylate12$2,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Invega$102$399,25497 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$352$160,88371 claims
AbbVieVraylar$352$39,40225 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$756$23,54614 claims
Almatica Pharma LLCSertraline Hcl$15$1,216196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →